Colesterol no-HDL: Utilidad clínica de un marcador de riesgo cardiovascular ignorado

Silvia F. Benozzi, Cristina A. Alvarez, Graciela L. Pennacchiotti

Resumen


Las enfermedades cardiovasculares constituyen la causa más importante de morbi-mortalidad del siglo XXI. Las lipoproteínas aterogénicas juegan un rol fundamental en el desarrollo de las mismas. La evaluación de estas lipoproteínas en el laboratorio de análisis clínicos se puede realizar mediante la determinación de colesterol no-HDL, que se obtiene de la diferencia entre colesterol total y el colesterol transportado por las lipoproteínas de alta densidad. Se ha demostrado que esta variable es mejor predictora de enfermedades cardiovasculares que la determinación de colesterol transportado por las lipoproteínas de baja densidad (LDL), por lo que entidades científicas sugieren su incorporación en todos los informes del perfil lipídico. Es una herramienta útil para estimar el riesgo cardiovascular y evaluar tratamientos que reduzcan ese riesgo. A pesar de que su obtención es rápida, sencilla y accesible a todos los laboratorios, continúa siendo un marcador poco solicitado.

 


Palabras clave


colesterol no-HDL; colesterol transportado por lipoproteínas de baja densidad; riesgo cardiovascular

Texto completo:

56-61

Referencias


Dahlöf B. Cardiovascular Disease Risk Factors: Epidemiology and Risk Assessment. Am J Cardiol 2010; 105:3-9.

Mertens A, Holvoet P. Oxidized LDL and HDL: antagonists in atherothrombosis. The FASEB Journal 2001; 15:2073-84.

Kawakami A., Yoshida M. Remmanent lipoproteins and aterogénesis. J Atheroscler Thromb 2005; 12:73-76.

Koschinsky ML. Lipoprotein (a) and atherosclerosis: new perspectives on the mechanism of action of an enigmatic lipoprotein. Curr Atheroscler Rep. 2005; 7(5):389-95.

Proctor SD, Vine DF, Mamo JC. Arterial retention of apolipoprotein B(48)- and B(100)-containing lipoproteins in atherogenesis. Curr Opin Lipidol 2002; 13: 461– 470.

Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. National Cholesterol Education Program: second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). Circulation. 1994; 89: 1329-1445.

Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Circulation 2002; 106:3143–3421.

Grundy SM. Approach to Lipoprotein Management in 2001 National Cholesterol Guidelines. Am. J. Cardiol. 2002; 90(suppl): 11i-21i.

Stampfer MJ., Krauss RM., Ma J., et al. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA. 1996; 276: 882-888.

Gardner CD., Fortmann SP., Krauss RM. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA. 1996; 276: 875-881.

Lamarche B., Lemieux I., Despres JP. The small, dense LDL phenotype and the risk of coronary heart disease: epidemiology, patho-physiology and therapeutic aspects. Diabetes Metab. 1999; 25: 199-211.

Austin MA. Triglyceride, small, dense low-density lipoprotein, and the atherogenic lipoprotein phenotype. Curr. Atheroscler. Rep. 2000; 2: 200-207

St-Pierre A.C., Ruel I.L., Cantin B., et al. Comparison of various electrophoretic characteristics of LDL particles and their relationship to the risk of ischemic heart disease. Circulation. 2001; 104: 2295-2299

Miller BD., Alderman EL., Haskell WL., Fair JM., Krauss RM. Predominance of dense low-density lipoprotein particles predicts angiographic benefit of therapy in the Stanford Coronary Risk Intervention Project. Circulation. 1996; 94: 2146-2153.

Kral BG., Becker LC., Yook RM., et al. Racial differences in low-density lipoprotein particle size in families at high risk for premature coronary heart disease. Ethn. Dis. 2001; 11: 325-337.

McNamara JR., Shah PK., Nakajima K., et al. Remnant-like particle (RLP) cholesterol is an independent cardiovascular disease risk factor in women: results from the Framingham Heart Study. Atherosclerosis. 2001; 154: 229- 236.

Schreuder PC., Twickler TB., Wang T., Nakajima K., Erkelens DW., Dallinga-Thie GM. Isolation of remnant particles by immunoseparation: a new approach for investigation of postprandial lipoprotein metabolism in normolipidemic subjects. Atherosclerosis. 2001; 157: 145-150

Ginsberg H. New perspectives on atherogenesis-role of abnormal triglyceride-rich lipoprotein metabolism. Circulation 2002; 106:2137–2142.

Brewer H. Hypertriglyceridemia: changes in the plasma lipoproteins associated with an increased risk of cardiovascular disease. Am J Cardiol 1999; 83:3F–12F.

Barter PJ, Ballantyne CM, Carmena R, et al. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/tencountry panel. J Intern Med 2006; 259:247–258.

Durrington PN, Bolton CH, Hartog M. Serum and lipoprotein, apolipoprotein levels in normal subjects and with hyperlipoproteinemia. Clin Chem Acta 1978; 82:151-60.

Ginsberg H. New perspectives on atherogenesis-role of abnormal triglyceride-rich lipoprotein metabolism. Circulation 2002; 106:2137– 2142.

Miller M, Ginsberg H.N, and Schaefer E.J. Relative Atherogenicity and Predictive Value of Non–High-Density Lipoprotein Cholesterol for Coronary Heart Disease. Am J Cardiol 2008; 101: 1003–1008.

McNamara JR, Jenner JL, Li Z, Wilson PW, Schaefer EJ. Change in LDL particle size is associated with change in plasma triglyceride concentration. Arterioscler Thromb 1992; 12:1284 –1290.

Contois JH, McConnell JP, Sethi AA, et al. Apolipoprotein B and Cardiovascular Disease Risk: Position Statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices Clinical Chemistry. 2009; 55:407-419.

Adult Treatment Panel III. Executive summary of the third report of the National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of high blood cholesterol in adults. JAMA. 2001; 285: 2484-2497

Brunzell JD, Davidson M, Furberg CD et al. Lipoprotein management in patients with cardiometabolic risk: conference report from the American Diabetes Association and the American College of Cardiology Foundation. JACC 2008; 51:1512–24.

Blaha MJ, Blumenthal RS, Brinton EA, Jacobson TA (on behalf of the National Lipid Association Taskforce on Non-HDL Cholesterol). The importance of non-HDL cholesterol reporting in lipid management. J Clin Lipidol 2008; 2:267–73.

Krauss RM. Atherogenicity of triglyceride-rich lipoproteins. Am J Cardiol 1998; 81:13B-17B.

Cui Y, Blumenthal S, Flaws JA, Whiteman M, Langenberg P, Bachorik PS, Bush T. Non–High-Density Lipoprotein Cholesterol levels as a predictor of cardiovascular disease mortality. Arch Intern Med 2001; 161: 1413-1419.

Vega G.L., Grundy S.M. Does measurement of apolipoprotein B have a place in cholesterol management? Arteriosclerosis. 1990; 10: 668-671.

Abate N., Vega G.L., Grundy S.M. Variability in cholesterol content and physical properties of lipoproteins containing apolipoprotein B-100. Atherosclerosis. 1993; 104: 159- 171.

Ahmad J., Abdur R.K, Faiz A, Sabah S. Non-HDL cholesterol versus Apolipoprotein B in the identification of dyslipidemic phenotypes associated with cardiovascular risk in type 2 diabetic dyslipoproteinemia Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2007; 1: 29-36

Okamura, T et al. Low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol and the incidence of cardiovascular disease in an urban Japanese cohort study: The Suita study. Atherosclerosis 2009; 203: 587–592

Liu J, Sempos CT, Donahue RP, Dorn J, Trevisan M, Grundy SM. Non-high-density Lipoprotein and very-low-density lipoprotein cholesterol and their risk predictive values in coronary heart disease. Am J Cardiol 2006; 98:1363–8.

Okamura T, Tanaka H, MiyamatsuN, et al. The relationship between serum total cholesterol and all-cause or cause-specific mortality in a 17, 3-year study of a Japanese cohort. Atherosclerosis 2007; 190:216–23.

Ridker PM, Rifai N, Cook NR, Bradwin G, Buring JE. Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA 2005; 294:326–33.

Pischon T, Girman CJ, Sacks FM, Rifai N, Stampfer MJ, Rimm EB. Non-high density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation 2005; 112:3375–83.

Jiang R, Schulze MB, Li T, et al. Non-HDL cholesterol and apolipoprotein B predict cardiovascular disease events among men with type 2 diabetes. Diabetes Care 2004; 27:1991–7.

Lu W, Resnick HE, Jablonski KA, et al. Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: the strong heart study. Diabetes Care 2003; 26:16–23

Contreras F, Lares M, Castro J, Magaldi L, Velasco M. Determinación de colesterol-no-HDL en pacientes diabéticos e hipertensos. Archivos Venezolanos de Farmacología y Terapeútica 2008; 27(1):78-80.

- Nishizawa Y, Shoji T, Kakiya R, et al. Non–high-density lipoprotein cholesterol (non-HDL-C) as a predictor of cardiovascular mortality in patients with end-stage renal disease. Kidney International, 2003; 63(84): S117–S120.

- Shoji T, Kawagishi T, EmotoM, et al: Additive impacts of diabetes and renal failure on carotid atherosclerosis. Atherosclerosis 2000; 153:257–258.

- Shoji T, Nishizawa Y, Kawagishi T, et al: Intermediate-density lipoprotein as an independent risk factor for aortic atherosclerosis in hemodialysis patients. J Am Soc Nephrol 1998; 9:1277–1284.

- Shoji T, Emoto M, Shinohara K, et al. Diabetes mellitus, aortic stiffness, and cardiovascular mortality in end-stage renal disease. J Am Soc Nephrol 2001; 12:2117–2124.

- Badiou S., Thiebaut R., Aurillac-Lavignolle V., et al. Association of non-HDL cholesterol with subclinical atherosclerosis in HIV-positive patients. Journal of Infection 2008; 57: 47-54.

Ballantyne CM., Raichlen JS., Cain VA. Statin Therapy Alters the Relationship Between Apolipoprotein B and Low-Density Lipoprotein Cholesterol and Non–High-Density Lipoprotein Cholesterol Targets in High-Risk Patients The MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY II) Trial. JACC 2008; 52 ; 8 :626–32.

Bittner V, Hardison R, Kelsey S, Weiner B, Jacobs A, Sopko G. Non–high-density lipoprotein cholesterol levels predict five-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI). Circulation 2002; 106:2537–2542.


Enlaces refback

  • No hay ningún enlace refback.


Copyright (c) 2019 Silvia F. Benozzi, Cristina A. Alvarez, Graciela L. Pennacchiotti



Asociación Médica de Bahía Blanca - Castelli 213 - B8000AIE Bahía Blanca - Buenos Aires - Argentina - https://www.ambb.org.ar